Department of Obstetrics & Gynecology, University of California, Irvine, Medical Center, Orange, CA; Miller Children's and Women's Hospital, Long Beach Memorial, Long Beach, CA.
Department of Obstetrics & Gynecology, University of California, Irvine, Medical Center, Orange, CA.
Am J Obstet Gynecol. 2015 Sep;213(3):415.e1-8. doi: 10.1016/j.ajog.2015.05.030. Epub 2015 May 21.
The purpose of this study was to determine tissue concentrations of cefazolin after the administration of a 3-g prophylactic dose for cesarean delivery in obese women (body mass index [BMI] >30 kg/m(2)) and to compare these data with data for historic control subjects who received 2-g doses. Acceptable coverage was defined as the ability to reach the minimal inhibitory concentration (MIC) of 8 μg/mL for cefazolin.
We conducted a 2-phase investigation. The current phase is a prospective cohort study of the effects of obesity on tissue concentrations after prophylactic 3-g cefazolin doses at the time of cesarean delivery. Concentration data after 3-g were compared with data for historic control subjects who had received 2-g. Three grams of parenteral cefazolin was given 30-60 minutes before skin incision. Adipose samples were collected at both skin incision and closure. Cefazolin concentrations were determined with the use of a validated high-performance liquid chromatography assay.
Twenty-eight obese women were enrolled in the current study; 29 women were enrolled in the historic cohort. BMI had a proportionally inverse relationship on antibiotic concentrations. An increase of the cefazolin dose dampened this effect and improved the probability of reaching the recommended MIC of ≥8 μg/mL. Subjects with a BMI of 30-40 kg/m(2) had a median concentration of 6.5 μg/g (interquartile range [IQR], 4.18-7.18) after receiving 2-g vs 22.4 μg/g (IQR, 20.29-34.36) after receiving 3-g. Women with a BMI of >40 kg/m(2) had a median concentration of 4.7 μg/g (IQR, 3.11-4.97) and 9.6 μg/g (IQR, 7.62-15.82) after receiving 2- and 3-g, respectively. With 2 g of cefazolin, only 20% of the cohort with a BMI of 30-40 kg/m(2) and none of the cohort with a BMI of >40 kg/m(2) reached an MIC of ≥8 μg/mL. With 3-g, all women with a BMI of 30-40 kg/m(2) reached target MIC values; 71% of the women with a BMI of >40 kg/m(2) attained this cutoff.
Higher adipose concentrations of cefazolin were observed after the administration of an increased prophylactic dose. This concentration-based pharmacology study supports the use of 3 g of cefazolin at the time of cesarean delivery in obese women. Normal and overweight women (BMI <30 kg/m(2)) reach adequate cefazolin concentrations with the standard 2-g dosing.
本研究旨在确定肥胖女性(体重指数 [BMI] >30 kg/m(2))接受剖宫产术预防性 3 克头孢唑林给药后的组织浓度,并与接受 2 克剂量的历史对照受试者的数据进行比较。可接受的覆盖范围定义为达到头孢唑林最低抑菌浓度(MIC)8μg/mL 的能力。
我们进行了两阶段研究。当前阶段是一项前瞻性队列研究,研究肥胖对剖宫产术预防性 3 克头孢唑林剂量后的组织浓度的影响。3 克后的浓度数据与接受 2 克的历史对照受试者的数据进行比较。在切开皮肤前 30-60 分钟给予 3 克静脉注射头孢唑林。在切开皮肤和关闭时采集脂肪样本。使用经过验证的高效液相色谱法测定头孢唑林浓度。
当前研究纳入了 28 名肥胖女性;历史队列纳入了 29 名女性。BMI 与抗生素浓度呈反比关系。增加头孢唑林剂量可以减弱这种影响,并提高达到推荐 MIC ≥8μg/mL 的可能性。BMI 为 30-40kg/m(2)的受试者接受 2g 后中位浓度为 6.5μg/g(四分位距 [IQR],4.18-7.18),接受 3g 后中位浓度为 22.4μg/g(IQR,20.29-34.36)。BMI>40kg/m(2)的女性接受 2g 后中位浓度为 4.7μg/g(IQR,3.11-4.97),接受 3g 后中位浓度为 9.6μg/g(IQR,7.62-15.82)。使用 2g 头孢唑林,BMI 为 30-40kg/m(2)的队列中只有 20%达到 MIC ≥8μg/mL,BMI>40kg/m(2)的队列中无一例达到。使用 3g 时,BMI 为 30-40kg/m(2)的所有女性均达到目标 MIC 值;BMI>40kg/m(2)的女性中有 71%达到该临界值。
给予较高预防性剂量后,头孢唑林的脂肪浓度更高。这项基于浓度的药物研究支持在肥胖女性剖宫产时使用 3g 头孢唑林。正常和超重女性(BMI<30kg/m(2))使用标准 2g 剂量可达到足够的头孢唑林浓度。